Quote:

---

No one is going to pay 100 million for ESS without first having a successful phase 2 trial done- too much risk.

---

The phase 2 is for adult burns with the Doc. They are planning two phase 3's


Amarantus is planning three distinct clinical development programs for ESS, all of which have the opportunity to gain rapid market approval in various orphan dermatologic conditions:

1- Adult severe burns: Initiating a 10-patient Phase II clinical development program with US Army study under CRADA at ISR and two additional leading civilian burn center

2- Pediatric severe burns: Evaluating Phase III development program designs with leading pediatric burn center(s) in the United State

3- Giant Congenital Melanocytic Nevi (GCMN): Evaluating pivotal Phase III development program designs with leading dermatology center(s) in the United States


http://scr.zacks.com/News/Press-Releases/Pres...fault.aspx